Login to Your Account



Clinic Roundup


Tuesday, September 6, 2011
Dr. Reddy's Laboratories Ltd., of Hyderabad, India, initiated a randomized, double-blind, placebo-controlled Phase II trial of DRL-17822 in Type II diabetes. The primary outcome is elevation in HDL cholesterol and reduction in LDL cholesterol.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription